FIELD: medicine, biochemistry, nucleic acids. SUBSTANCE: invention relates to the purified and isolated RNA-ligands no occurring in nature to vesical endothelial growth factor (VEGF) where oligonucleotide sequences are indicated. Invention describes complexes of the formula A-B-Y where A means polyalkyl ne glycol or glycerol lipid; B means linker(s); Y means RNA-ligand to VEGF. Invention describes method of synthesis of these complexes including identification of RNA-ligand from a mixture of nucleic acid candidates eliciting the enhanced affinity to VEGF and lipid structure including this complex. Complexes improve pharmacokinetic properties of RNA-ligands to VEGF and used for treatment of patients with VEGF-mediated diseases, among them, for inhibition of VEGF- mediated angiogenesis, tumors growth and degeneration of yellow spot. Invention proposes also method of clearance decrease of nucleic acid-ligand to VEGF from plasma, method of prolongation of its effect in eye and method of direction of therapeutic or diagnostic agent to biological target. EFFECT: valuable properties of complexes. 77 cl, 34 dwg, 13 tbl, 11 ex
Title |
Year |
Author |
Number |
MODIFIERS OF GLYCOPROTEIN VI REPRESENTING NUCLEIC ACID |
2010 |
- Lehjzer Dzhuliana M.
- Raskoni Kristofer P.
- Bruks Duglas
- Zelenkofske Stiven L.
|
RU2571660C2 |
CONJUGATES PRODUCED FROM METAL AND OLIGONUCLEOTIDE COMPLEXES, MEANS CONTAINING THE CONJUGATES, METHOD FOR PRODUCING AND USING THE CONJUGATES IN RADIOLOGICAL DIAGNOSIS |
1995 |
- Ludger Dinkel'Borg
- Kristof-Shtefan Khil'Ger
- Ul'Rikh Nidballa
- Jokhannes Plattsek
- Bernd Radjukhel'
- Ul'Rikh Shpek
- Larri Gold
- Vol'Fgang Piken
|
RU2165771C2 |
METHOD OF IDENTIFICATION OF LIGANDS, METHOD OF ANTIBODY PREPARING, METHOD OF SELECTION OF NUCLEIC ACID, METHOD OF NUCLEIC ACIDS MIXTURE PREPARING, MIXTURE OF NUCLEIC ACIDS, NUCLEIC ACID LIGAND NO OCCURRING IN NATURE |
1991 |
|
RU2198931C2 |
INTRODUCTION OF ANTICOAGULATIVE SYSTEM REG1 |
2007 |
- Raskoni Kristofer P.
- Tonkens Ross M.
|
RU2464030C2 |
METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS, DIRECTLY ACTING ON CONNECTIVE TISSUE GROWTH FACTOR (CTGF) |
2012 |
- Din Nikolas M.
- Krochmel Linkoln
- Khardi Gregori
- Foulkes Dzh. Gordon
- O`Donnell Najall
- Yang Leroj
- Dzheuell Mark
|
RU2608655C2 |
COMPOSITIONS AND METHODS FOR APOLIPOPROTEIN C-III (APOC3) GENE EXPRESSION INHIBITION |
2012 |
- Bettenkort Brajan
- Fittszherald Kevin
- Milstejn Styuart
- Majer Martin
- Kharisse Klaus
- Radzhiv Kallantkhottatkhil
- Kuchimanchi Satiya
- Manokharan Mutkhiakh
- Nguejn Tujen
|
RU2631805C2 |
METHOD OF IDENTIFICATION OF COMPONENTS FROM MIXTURE, COMPONENT OBTAINED IN IDENTIFICATION, METHOD OF PREPARING MIXTURE AND METHOD OF COMBINED PREPARING CATALYZING NUCLEIC ACID AND COMPONENT |
1995 |
|
RU2132853C1 |
COMPLEXES BASED ON MICRO-BUBBLES AND METHODS OF APPLICATION |
2012 |
|
RU2613321C2 |
TREATMENT OF DISEASES ASSOCIATED WITH ERYTHROPOIETIN (EPO) BY NATURAL EPO ANTISENSE TRANSCRIPT INHIBITION |
2009 |
- Kollard Dzhozef
- Khorkova Sherman Olga
|
RU2620970C2 |
TREATING DISEASES ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) BY SUPPRESSION OF NATURAL ANTISENSE VEGF TRANSCRIPT |
2009 |
- Kollard Dzhozef
- Khor'Kova Sherman Ol'Ga
|
RU2569182C2 |